May 23,2022

Swiss multicentre study to investigate the effect of ePRO-based model of care on early detection and management of immune-related adverse events

Kaiku Health is taking part in a study assessing the use of an electronic Patient-Reported Outcome (ePRO)-based model of care to evaluate onset of symptomatic immune-related adverse events in cancer patients and their detection by healthcare providers. This phase-II randomised controlled trial, comparing the ePRO-based model of care to the current standard model of care, is conducted at the Geneva University Hospitals and Lausanne University Hospital, Switzerland.

CLINICAL STUDY

#rpm

View Analyst & Ambassador Comments
Go to original news
May 31,2022

OncoHealth and Blue Note Therapeutics Partner to Provide a Digital Therapeutic for Treating Cancer-Related Anxiety and Depression Symptoms

Blue Note Therapeutics, a prescription digital therapeutics (PDT) company dedicated to easing the burden of cancer and improving outcomes, and OncoHealth, a leading digital health company dedicated to oncology, have partnered to support patients coping with cancer by delivering oncology-specific mental health care. Through OncoHealth's telehealth platform, Iris™, licensed healthcare professionals will now provide Blue Note's attune™ to patients living with cancer. Blue Note developed attune as an “on-demand” self-directed tool for patients with cancer. 

COLLABORATION PARTNERSHIP

#institution

#pdt

View Analyst & Ambassador Comments
Go to original news
Jun 01,2022

Attune Ensemble™ OTC, a First of its Kind Cancer Well-Being App, is Now Available for Free to Spanish-Speaking Patients

Blue Note Therapeutics today announced plans to provide Spanish-speaking patients with immediate access to a new cancer-specific wellness app, attune ensemble™ OTC. The wellness app is a first-of-its-kind digital therapy designed to help patients cope with the emotional symptoms of cancer, such as stress. Providing attune ensemble OTC in Spanish supports Blue Note’s goal of providing all patients with access to cancer-specific support to ease the burdens of cancer and improve outcomes.

PRODUCT

#pdt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 17,2022

Sidekick Health and Eli Lilly partner on digital therapeutics for breast cancer

Sidekick Health today announced a collaboration on an integrated digital therapeutics solution in conjunction with Eli Lilly (NYSE:LLY). The collaboration between the companies will mark the first phase of a relationship between Sidekick and Lilly, which starts with a digital therapeutic offering for patients battling breast cancer. The first phase will consist of the integrated digital therapeutic offering rollout in Germany. Reykjavik, Iceland-based Sidekick said the further expansion of its portfolio of digital therapeutics into the treatment of breast cancer will be tailored to support the needs of patients within Lilly’s oncology treatment programs.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 25,2022

First-of-its-kind partnership provides free access to digital mental health treatments for all newly diagnosed cancer patients in the United Kingdom

Newly diagnosed cancer patients across the United Kingdom (UK) are now able to easily access innovative and effective treatments to support their mental health thanks to a new partnership between Macmillan Cancer Support and digital therapeutics company Big Health, makers of Sleepio and Daylight. The partnership between Macmillan and Big Health will provide newly diagnosed cancer patients aged 18 and older residing in England, Wales, and Northern Ireland free access to Sleepio for insomnia and Daylight for anxiety to manage their mental health needs.

COLLABORATION PARTNERSHIP

#institution

#cbt

View Analyst & Ambassador Comments
Go to original news
Aug 31,2022

Kaiku Health expands partnership with a leading global medicines company to provide improved cancer care to more patients across multiple indications

Last year Kaiku Health, a leading digital therapeutics platform for cancer care, announced its collaboration with Novartis, a leading global medicines company, in developing digital patient monitoring and management for melanoma patients. Following the success of the collaboration, Kaiku Health and Novartis are now expanding it into a partnership.

COLLABORATION PARTNERSHIP

#product & service

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 05,2022

Results presented at ESMO 2022: Kaiku Health digital patient monitoring platform can help in resolving acute fever in melanoma patients

A multicenter study led by the Netherlands Cancer Institute used Kaiku Health digital patient management platform to investigate the use of digital patient monitoring and support of patients with advanced melanoma. The results published at ESMO 2022 annual conference suggest that Kaiku Health can be used to support patients and to collect real-world evidence. They can also help to understand the development of symptoms and quality of life of the patients.

CLINICAL STUDY

#rwe

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 08,2022

Ypsomed & Sidekick Health Partner to Improve Therapy Outcomes

Ypsomed and Sidekick Health today announced a collaboration to extend Ypsomed’s device and SmartServices offering by implementing a self-injection module in Sidekick’s proven digital therapeutics solution. The combination of Ypsomed’s devices with Sidekick’s digital health, behavioural economics and gamification expertise will form a unique solution delivering an engaging and personalized patient experience to people with chronic conditions, as well as a turn-key, best-in-class digital therapy management system for pharmaceutical customers. The two companies will jointly develop a set of features and behavioural interventions that support and empower patients throughout the self-injection process and beyond for areas such as oncology, immunology or metabolic diseases.

COLLABORATION PARTNERSHIP

#r&d

#software

View Analyst & Ambassador Comments
Go to original news
Aug 01,2021

Durham VA Health Care System and Blue Note Therapeutics Commence Phase 2 Study of Prescription Digital Therapeutic to Address Cancer-Related Distress

On August 2, 2021, the Durham Veterans Affairs (VA) Health Care System and Blue Note Therapeutics announced a partnership to address cancer-related distress in veterans. With approximately 40,000 veterans diagnosed with cancer each year, and nearly all experiencing some form of distress, there is an immediate opportunity to improve and expand access to quality mental health care for veterans living with cancer. The partnership includes a clinical study of a prescription digital therapeutic (PDT) created specifically for patients suffering from cancer-related distress. The Phase 2 study will assess the feasibility, ease of clinical implementation, and preliminary efficacy of BNT001, Blue Note’s lead PDT candidate.

COLLABORATION PARTNERSHIP

#r&d

#pdt

View Analyst & Ambassador Comments
Go to original news
Sep 01,2021

Blue Note Therapeutics Raises $5.2M in Additional Series A Funding

Blue Note Therapeutics raised an additional $5.2 million in Series A financing, bringing the company’s Series A financing to a total of $31 million. The financing was provided by Memorial Sloan Kettering Cancer Center (MSK) and Alumni Ventures who joined Series A lead investors JAZZ Venture Partners and Summer VC.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY